Cergentis releases new Application Note on MRD detection7 June 2017
Cergentis has released a new application note on the use of gene fusion breakpoints for sensitive detection of MRD in pediatric leukaemia and lymphoma.
The Targeted Locus Amplification (TLA) technology can be used to detect the exact patient-specific breakpoint of a disease-causing mutation in leukaemia patients.
Minimal residual disease (MRD), is an indication of a relapse occurring in the patient and is thus a critical parameter for monitoring progress after treatment.
Conventional MRD detection methods cannot always be applied, making it difficult for the physician to monitor the potential relapse in a patient.
Together with renowned European leukaemia labs, Cergentis has utilised the TLA technology to detect patient-specific breakpoints of disease-causing gene fusions. The breakpoints are then subsequently used by the labs to design a conventional breakpoint-specific qPCR strategy for MRD monitoring of the patients after treatment.
In the new application note, we show that the breakpoint-based methodology provides a sensitive and comparable alternative for MRD detection compared to current methodologies.